Show simple item record

dc.contributor.authorBosas, Paulius
dc.contributor.authorZaleskis, Gintaras
dc.contributor.authorDabkevičienė, Daiva
dc.contributor.authorDarulytė, Neringa
dc.contributor.authorMlynska, Agata
dc.contributor.authorTikuišis, Renatas
dc.contributor.authorUlys, Albertas
dc.contributor.authorPašukonienė, Vita
dc.contributor.authorJarmalaitė, Sonata
dc.contributor.authorJankevičius, Feliksas
dc.date.accessioned2023-09-18T16:08:12Z
dc.date.available2023-09-18T16:08:12Z
dc.date.issued2021
dc.identifier.issn2077-0383
dc.identifier.other(PMID)34442004
dc.identifier.urihttps://etalpykla.vilniustech.lt/handle/123456789/111603
dc.description.abstractBACKGROUND: Prostate cancer (PCa) is known to exhibit a wide spectrum of aggressiveness and relatively high immunogenicity. The aim of this study was to examine the effect of tumor excision on immunophenotype rearrangements in peripheral blood and to elucidate if it is associated with biochemical recurrence (BCR) in high risk (HR) and low risk (LR) patients. METHODS: Radical prostatectomy (RP) was performed on 108 PCa stage pT2-pT3 patients. Preoperative vs. postoperative (one and three months) immunophenotype profile (T- and B-cell subsets, MDSC, NK, and T reg populations) was compared in peripheral blood of LR and HR groups. RESULTS: The BCR-free survival difference was significant between the HR and LR groups. Postoperative PSA decay rate, defined as ePSA, was significantly slower in the HR group and predicted BCR at cut-off level ePSA = -2.0% d-1 (AUC = 0.85 (95% CI, 0.78-0.90). Three months following tumor excision, the LR group exhibited a recovery of natural killer CD3 - CD16+ CD56+ cells, from 232 cells/µL to 317 cells/µL (p < 0.05), which was not detectable in the HR group. Prostatectomy also resulted in an increased CD8+ population in the LR group, mostly due to CD8+ CD69+ compartment (from 186 cells/µL before surgery to 196 cells/µL three months after, p < 001). The CD8+ CD69+ subset increase without total T cell increase was present in the HR group (p < 0.001). Tumor excision resulted in a myeloid-derived suppressor cell (MDSC) number increase from 12.4 cells/µL to 16.2 cells/µL in the HR group, and no change was detectable in LR patients (p = 0.12). An immune signature of postoperative recovery was more likely to occur in patients undergoing laparoscopic radical prostatectomy (LRP). Open RP (ORP) was associated with increased MDSC numbers (p = 0.002), whereas LRP was characterized by an immunity sparing profile, with no change in MDSC subset (p = 0.16). CONCLUSION: Tumor excision in prostate cancer patients results in two distinct patterns of immunophenotype rearrangement. The low-risk group is highly responsive, revealing postoperative restoration of T cells, NK cells, and CD8+ CD69+ numbers and the absence of suppressor MDSC increase. The high-risk group presented a limited response, accompanied by a suppressor MDSC increase and CD8+ CD69+ increase. The laparoscopic approach, unlike ORP, did not result in an MDSC increase in the postoperative period.eng
dc.formatPDF
dc.format.extentp. 1-15
dc.format.mediumtekstas / txt
dc.language.isoeng
dc.relation.isreferencedbyScience Citation Index Expanded (Web of Science)
dc.relation.isreferencedbyScopus
dc.relation.isreferencedbyPubMed
dc.rightsLaisvai prieinamas internete
dc.source.urihttps://doi.org/10.3390/jcm10163709
dc.source.urihttps://talpykla.elaba.lt/elaba-fedora/objects/elaba:103399780/datastreams/MAIN/content
dc.titleImmunophenotype rearrangement in response to tumor excision may be related to the risk of biochemical recurrence in prostate cancer patients
dc.typeStraipsnis Web of Science DB / Article in Web of Science DB
dcterms.accessRightsThis article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
dcterms.licenseCreative Commons – Attribution – 4.0 International
dcterms.references55
dc.type.pubtypeS1 - Straipsnis Web of Science DB / Web of Science DB article
dc.contributor.institutionVilniaus universitetas
dc.contributor.institutionNacionalinis vėžio institutas
dc.contributor.institutionNacionalinis vėžio institutas Vilniaus Gedimino technikos universitetas
dc.contributor.institutionNacionalinis vėžio institutas Vilniaus universitetas
dc.contributor.institutionVilniaus universitetas Vilniaus universiteto ligoninė Santaros klinikos
dc.contributor.facultyFundamentinių mokslų fakultetas / Faculty of Fundamental Sciences
dc.subject.researchfieldM 001 - Medicina / Medicine
dc.subject.researchfieldN 010 - Biologija / Biology
dc.subject.researchfieldN 004 - Biochemija / Biochemistry
dc.subject.vgtuprioritizedfieldsFM0202 - Ląstelių ir jų biologiškai aktyvių komponentų tyrimai / Investigations on cells and their biologically active components
dc.subject.ltspecializationsL105 - Sveikatos technologijos ir biotechnologijos / Health technologies and biotechnologies
dc.subject.enprostate cancer
dc.subject.enprostatectomy
dc.subject.enbiochemical recurrence
dc.subject.enimmunophenotyping
dcterms.sourcetitleJournal of clinical medicine: Special Issue Recent Advances in Prostate Cancer Treatment
dc.description.issueiss. 16
dc.description.volumevol. 10
dc.publisher.nameMDPI
dc.publisher.cityBasel
dc.identifier.doi34442004
dc.identifier.doi3709
dc.identifier.doi000689109500001
dc.identifier.doi10.3390/jcm10163709
dc.identifier.elaba103399780


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record